) has secured a manufacturing and commercial supply agreement worth approximately ₹423 crore from a large domestic pharmaceutical company for the supply of pen injectors, with execution scheduled over a 4-year period. The order enhances the company’s revenue visibility and reinforces its growing presence in the high-value healthcare devices segment, where demand for advanced drug-delivery systems continues to rise. Importantly, the company clarified that the transaction is conducted on an arm’s-length basis with no related-party involvement, underscoring governance transparency.

#FundamentalViews#WatchOutFor#StockInNews#EquityResearch#Miscellaneous

2 likes